IV PPI is indicated in the treatment of high-risk peptic ulcers, complicated gastroesophageal reflux, stress-induced ulcer prophylaxis, Zollinger–Ellison syndrome, and whenever it is impossible or impractical to give oral therapy. The widespread use of PPIs has been controversial.

Proton pump inhibitors (PPIs) have been in use since the early 1990s and play a crucial role in the management of a number of conditions affecting the upper gastrointestinal tract, including gastroesophageal reflux disease, Barrett esophagus, eosinophilic esophagitis, and dyspepsia.

May 31, 2024 · Gastroesophageal reflux disease – PPIs are indicated in patients with gastroesophageal reflux disease, including for the treatment of erosive esophagitis and as maintenance therapy in patients with severe erosive esophagitis or Barrett’s esophagus.

Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor (PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding ulcers.

Dec 17, 2019 · NSAID-induced gastroduodenal ulcers are estimated to account for thousands of gastrointestinal (GI) complications each year, including GI bleeds, gastric pain, or even death. 8 Currently, PPIs are recommended and FDA-approved as chronic prophylaxis in individuals with high risk due to concurrent and planned long-term NSAID use, as well as ...

Optimizing proton pump inhibitor therapy for treatment of non-variceal upper gastrointestinal bleeding Although the current guidelines recommend an IV bolus injection followed by continuous infusion of a high-dose PPI, intermittent PPI therapy has been found to be safe and effective while significantly reducing cost, even in patients with high ...

Jun 14, 2024 · Proton-pump inhibitors were associated with a reduced incidence of clinically important upper gastrointestinal bleeding (relative risk [RR], 0.51 [95% confidence interval (CI), 0.34 to 0.76];...

Infusion with proton pump inhibitors (PPIs) prevents recurrent bleeding after successful endoscopic therapy. A gastric acidic environment of less than pH 5.4 alters coagulation function and activates pepsin to disaggregate platelet plugs.

Background: Proton pump inhibitor (PPI) continuous infusions or intermittent boluses are used for the treatment of upper gastrointestinal bleeding (UGIB). Intermittent boluses are easier to give and are of lower cost without affecting clinical outcomes.

Situations where intravenous PPIs may be used: Patients who, at endoscopy, are found to have a peptic ulcer deemed to be at high risk of re-bleeding; these are actively bleeding ulcers or non-bleeding ulcers with a visible vessel.